Stemline Therapeutics reports 3Q loss Thu, 09 Nov 2017 22:14:01 +0000 The New York-based company said it had a loss of 68 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
Stemline Therapeutics Reports Third Quarter 2017 Financial Results Thu, 09 Nov 2017 21:01:00 +0000 NEW YORK, Nov. 09, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today financial results for the ...
Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting Wed, 01 Nov 2017 13:02:00 +0000 NEW YORK, Nov. 01, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that SL-401, a novel targeted ...
Stemline Therapeutics to Present at Upcoming Investor Conferences Wed, 20 Sep 2017 11:00:00 +0000 NEW YORK, Sept. 20, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced that Ivan Bergstein, M.D., Stemline’ ...
Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017 Mon, 11 Sep 2017 11:00:00 +0000 NEW YORK, Sept. 11, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced the presentation of clinical data ...
ETFs with exposure to Stemline Therapeutics, Inc. : September 1, 2017 Fri, 01 Sep 2017 01:14:58 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Stemline Therapeutics, Inc. Here are 5 ETFs with the largest exposure to STML-US. Comparing the performance and risk of Stemline Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress Wed, 30 Aug 2017 22:10:00 +0000 NEW YORK, Aug. 30, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that data from SL-801’ s ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.